You are here:

MS in the media - 7 October 2016

Published on

1 - 7 October 2016

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

ESA re-assessments

The government have announced that they are to scrap reassessment of people claiming ESA (Employment Support Allowance) if they have a condition that is unlikely to have improved.  The Work and Pensions Secretary said, "constant reassessment is pointless and increases stress and anxiety levels.”

Source: BBC
Source: Guardian

MS Trust link: Benefits

NICE turns down daclizumab

NICE's initial recommendation is that daclizumab (Zinbryta) is not recommended for treating relapsing forms of MS.  The decision, which affects England and Wales, is open for consultation until 21 October

Source: NICE

MS Trust link: NICE says no to daclizumab (Zinbryta) - MS Trust news item (3 October)

Mindfulness helps with coping

A study, which included people with MS, found that mindfulness helped people with a long-term medical conditions to cope their diagnosis.

Source: De Montfort University

MS Trust link: Mindfulness

Tysabri vs Gilenya comparison

Research that compared three previous clinical studies found that Tysabri (natalizumab) was associated with a lower relapse rate and better chance of NEDA (no evidence of disease activity) than Gilenya (fingolimod), though there was no difference on disease progression.  Comparisons from five observational studies found the two drugs had a similar effect on relapse rate and disability progression, but people on Tysabri were more likely to be remain relapse-free after two years.

Source: MS News Today

MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing MS